Gilead Sciences· @GileadSciences · X·· 2026-07-24精选AI 评分62
AI 导读
吉利德宣布其联合方案获得 CHMP 正面意见，用于 PD-(L)1 阳性一线转移性三阴性乳腺癌。若获批，欧洲 PD-(L)1 阳性 mTNBC 患者将获得新的治疗选择。
推荐理由
CHMP 正面意见是三阴性乳腺癌联合方案进入欧洲市场的关键一步，读者可据此了解该适应症的监管进展。
正文
#GileadNews: We received a #CHMP positive opinion for our combination regimen in PD-(L)1-positive first-line metastatic triple-negative breast cancer. If approved, patients with PD-(L)1 positive mTNBC will have a new treatment option in Europe. https://gilead.inc/4vIE7XN
来源：Gilead Sciences · x.com